Urinary Glycosaminoglycans: Characterization and Quantification
Author:
Fdil Naima,Sabir Es-Said
Reference10 articles.
1. Fdil N, Sabir E-S, Ezoubeiri A et al (2020) Implementation of an affordable method for MPS diagnosis from urine screening to enzymatic confirmation: results of a pilot study in Morocco. Clin Lab 66. https://doi.org/10.7754/Clin.Lab.2019.190720
2. Sabir E, Lafhal K, Ezoubeiri A et al (2020) Usefulness of urinary glycosaminoglycans assay for a mucopolysaccharidosis-specific screening. Pediatr Int 62:1077–1085
3. Shimada T, Tomatsu S, Mason RW, et al (2014) Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis II, IVA, and IVB. In: JIMD reports, vol 21. Springer, pp 1–13
4. Kakkis E, Marsden D (2020) Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. Mol Genet Metab 130:7–15
5. Gandhi NS, Mancera RL (2008) The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455–482